Trial · NCT05724589
The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.
NCT05724589, Not applicable, Completed, Institute of Dermatology, Thailand; results first posted 2025-07-31
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles. Trials, record NCT05724589. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05724589
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.
- NCT number
- NCT05724589
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 28 participants, actual
- Lead sponsor
- Institute of Dermatology, Thailand
- Conditions
- Aging
- Interventions
- Epidermal Growth Factor
- First posted
- 2023-02-13
- Last updated
- 2025-07-31
- Results first posted
- 2025-07-31
- Limitations and caveats
- The small sample size should be considered. Further research involving a larger population or control group is recommended for conclusive insights into the efficacy of EGF serum.
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Facial Skin Hydration | 4 months (Baseline, Week 8, Week 12, Week 16) | Facial skin hydration was measured using a Corneometer, which provides readings in arbitrary units (a.u.). Measurements were taken at baseline (Day 0), Week 8, Week 12, and Week 16 under standardized environmental and procedural conditions to ensure reliability and accuracy. Higher values indicate better skin hydration, while lower values indicate increased dryness. |
| Primary | Transepidermal Water Loss | 4 months | measured by tewameter on day 0, then at 8, 12, and 16 weeks. |
| Primary | Facial Skin Elasticity (R2 Parameter Via Cutometer) | Baseline, Week 8, Week 12, Week 16 | Skin elasticity was assessed using a Cutometer with the R2 parameter (Ua/Uf), which measures gross elasticity. R2 values range from 0 to 1.0, with higher values indicating better skin elasticity. Measurements were collected under standardized conditions at Baseline (Day 0), Week 8, Week 12, and Week 16. |
| Primary | Facial Skin Wrinkles | 4 months | Visioscan measurements were taken at baseline, then at 8, 12, and 16 weeks by using a 4-grade percentage wrinkle improvement scale. |
| Primary | Facial Melanin Index | 4 months | Facial pigmentation was assessed using the Mexameter, which measures melanin content via light absorption and reflection. The device reports values on a scale from 0 to 999, where higher values represent greater melanin concentration. Measurements were collected at standardized facial sites at Baseline, Week 8, Week 12, and Week 16. Higher scores indicate worse pigmentation. |
| Primary | Overall Facial Skin Appearance (Photo Evaluation Using SGAIS) | 4 months | Facial skin appearance was evaluated using the Subject Global Aesthetic Improvement Scale (SGAIS), a 5-point scale where higher scores indicate greater improvement. Scores were assigned by two board-certified dermatologists who assessed photographs taken by the Visia-CR imaging system at Baseline, Week 8, Week 12, and Week 16. SGAIS scoring definition: 1 = Worse, 2 = Mild improvement (\<25%), 3 = Moderate (25-49%), 4 = Much improved (50-74%), 5 = Very much improved (≥75%). |
| Secondary | Subject Satisfaction in Improving Skin Hydration, Elasticity, Wrinkles, and Pigmentation | 4 months | Using a quartile grading system, (0 = unsatisfied), (1 = slightly satisfied), (2 = satisfied), and (3 = very satisfied) |
| Secondary | Adverse Events | 4 months | Adverse events were systematically monitored at 2, 4, 8, 12, and 16 weeks post-treatment initiation. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Facial Skin Hydration | 4 months (Baseline, Week 8, Week 12, Week 16) | The analysis population included 28 subjects initially recruited for this study. Participants were assessed at four time points: baseline (Day 0), Week 8, Week 12, and Week 16. One participant was lost to follow-up after Week 12 and Week 16. | arbitrary units | MEAN |
| PRIMARY | Transepidermal Water Loss | 4 months | The analysis population for this study on Transepidermal Water Loss (TEWL) utilizing Tewameter measurements comprised a total of 28 initially recruited subjects. These participants were assessed at four distinct time points: day 0 (baseline), 8 weeks, 12 weeks, and 16 weeks. One subject loss follow-up at week 12 and week 16. | g/m²·h | MEAN |
| PRIMARY | Facial Skin Elasticity (R2 Parameter Via Cutometer) | Baseline, Week 8, Week 12, Week 16 | 28 participants were assessed at Baseline and Week 8. One participant was lost to follow-up after Week 8, resulting in 27 participants at Weeks 12 and 16. Skin elasticity was measured using the R2 parameter from Cutometer readings at each time point. | units on a scale | MEAN |
| PRIMARY | Facial Skin Wrinkles | 4 months | The analysis population for this study on facial skin wrinkles using Visioscan included 28 subjects, assessed at Day 0 (baseline), Week 8, Week 12, and Week 16. One subject dropped out at Week 12 and another at Week 16, leaving data from 27 participants for Weeks 12 and 16. Wrinkle improvement was assessed on a 4-grade scale: Grade 1 (0-25%) = slight, Grade 2 (25-50%) = moderate, Grade 3 (50-75%) = marked, Grade 4 (\>75%) = significant. Data are presented as mean grades with standard deviation. | units on a scale | MEAN |
| PRIMARY | Facial Melanin Index | 4 months | The analysis population for this study on facial skin pigmentation utilizing Mexameter measurements comprised a total of 28 initially recruited subjects. These participants were assessed at four distinct time points: day 0 (baseline), 8 weeks, 12 weeks, and 16 weeks. One subject loss follow-up at week 12 and week 16. | unitless index | MEAN |
| PRIMARY | Overall Facial Skin Appearance (Photo Evaluation Using SGAIS) | 4 months | The analysis population included 28 subjects assessed at baseline, 8, 12, and 16 weeks. One participant was lost to follow-up after week 12. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Subject Satisfaction in Improving Skin Hydration, Elasticity, Wrinkles, and Pigmentation | 4 months | The assessment of participant satisfaction post-treatment involves all twenty-eight participants, with evaluations at 2, 3, and 4 months using a quartile grading system (0 = unsatisfied, 1 = slightly satisfied, 2 = satisfied, 3 = very satisfied). It is important to note that one subject was lost to follow-up since the 12-week mark. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Adverse Events | 4 months | The comprehensive evaluation encompassed a total of 28 subjects. One participant was lost to follow-up at the 12-week mark. Adverse events were systematically monitored through video calls at 2 and 4 weeks post-treatment initiation. On-site evaluations were conducted at 8, 12, and 16 weeks. At each time point, the number of participants analyzed was 28, with one participant lost to follow-up at the 12-week and 16-week evaluations. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group74
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Facial Skin Hydration | Epidermal Growth Factor Serum Application | Baseline | 56.043 | Standard Deviation 1.900 | arbitrary units |
| Facial Skin Hydration | Epidermal Growth Factor Serum Application | 8 weeks | 58.300 | Standard Deviation 1.567 | arbitrary units |
| Facial Skin Hydration | Epidermal Growth Factor Serum Application | 12 weeks | 55.852 | Standard Deviation 1.583 | arbitrary units |
| Facial Skin Hydration | Epidermal Growth Factor Serum Application | 16 weeks | 58.714 | Standard Deviation 1.568 | arbitrary units |
| Transepidermal Water Loss | Epidermal Growth Factor Serum Application | Baseline | 11.815 | Standard Deviation 1.221 | g/m²·h |
| Transepidermal Water Loss | Epidermal Growth Factor Serum Application | 8 weeks | 8.761 | Standard Deviation 0.623 | g/m²·h |
| Transepidermal Water Loss | Epidermal Growth Factor Serum Application | 12 weeks | 8.400 | Standard Deviation 0.516 | g/m²·h |
| Transepidermal Water Loss | Epidermal Growth Factor Serum Application | 16 weeks | 8.160 | Standard Deviation 0.559 | g/m²·h |
| Facial Skin Elasticity (R2 Parameter Via Cutometer) | Epidermal Growth Factor Serum Application | Baseline | 0.596 | Standard Deviation 0.016 | units on a scale |
| Facial Skin Elasticity (R2 Parameter Via Cutometer) | Epidermal Growth Factor Serum Application | 8 wk | 0.596 | Standard Deviation 0.013 | units on a scale |
1 to 10 of 74Source ClinicalTrials.gov
See all 74 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Epidermal Growth Factor Serum Application | 28 | 28 |
| Overall Study | COMPLETED | Epidermal Growth Factor Serum Application | 27 | 27 |
| Overall Study | NOT COMPLETED | Epidermal Growth Factor Serum Application | 1 | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Epidermal Growth Factor Serum Application | 0 | 28 |
| Total, other adverse events | Epidermal Growth Factor Serum Application | 0 | 28 |
| Total, serious adverse events | Epidermal Growth Factor Serum Application | 0 | 28 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05724589
GET https://conductscience.org/api/trials/v1/NCT05724589/results?page=2